Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC

Read More

Newsletter subscription

  • Enter your details

OCREVUS (Ocrelizumab) for primary progressive MS – November 2017 PBAC Agenda